Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Premium

Boss Energy (ASX:BOE) Ends FY25 with AUD 224M in Cash, Targets Positive Cash Flow in FY26

Boss Energy Limited (ASX:BOE) is an Australian uranium producer with operations in Australia and the United States. The flagship asset of BOE is Honeymoon Uranium Project in South Australia. In the year ended 30 June 2025 (FY25), the company recorded revenue of AUD 75.6 …

Sonal Goyal | 03 September 2025

FireFly Metals (ASX:FFM) Targets Copper-Gold Growth with Scoping Study and Resource Expansion Plans

FireFly Metals Limited (ASX:FFM) is an ASX-listed copper-gold developer focused on advancing the Green Bay Copper-Gold Project, located in Canada. The company also holds a majority stake in the Pickle Crow Gold Project in Canada and the Limestone Well Vanadium-Titanium Project in Western Australia.

Sonal Goyal | 02 September 2025

Macquarie Technology (ASX:MAQ) Reports FY25 Revenue Growth with Data Centre Expansion

Macquarie Technology Group Limited (ASX:MAQ) is an Australian data centre, cloud, cyber security, and telecom services provider. The company primarily serves mid-to-large businesses and government clients. In the 12 months ended 30 June 2025 (FY25), the company recorded revenue growth and continued investment in …

Sonal Goyal | 01 September 2025

SPC Global (ASX:SPG) Projects 25% EBITDA Growth in FY26 with Cost Synergies

SPC Global Holdings Ltd (ASX: SPG), formerly known as The Original Juice Co. Ltd, has outlined revenue growth, merger integration progress, and forward-looking targets in its recently announced financial results for the 12 months ended June 2025 (FY25). The Australia-based global food and beverage …

Sonal Goyal | 28 August 2025

Woodside Energy (ASX:WDS) Expands Portfolio with Bass Strait Acquisition, Announces Interim Dividend

Woodside Energy Group Limited (ASX:WDS), an Australia-based energy company with a diversified global portfolio, including LNG, condensate, crude oil, pipeline gas, and natural gas liquids. The company is engaged across the value chain, from exploration and development to production and sales, with assets both …

Sonal Goyal | 26 August 2025

Margin Pressures Weigh on Redox (ASX:RDX) FY25 Profit Despite 9.4% Revenue Rise

Redox Limited (ASX:RDX) is an international distributor of specialty and commodity chemicals, ingredients, and raw materials. In the year ended 30 June 2025 (FY25), the company reported a 9.4% YoY increase in sales revenue, reaching AUD 1,244 million. The growth was driven by higher …

Sonal Goyal | 25 August 2025

Bravura Solutions (ASX:BVS) Sets FY26 Priorities with Platform Enhancements and Market Expansion

Bravura Solutions Limited (ASX:BVS) is an international provider of software solutions for life insurance, funds administration industries and wealth management. In the full year ended 30 June 2025 (FY25), the company posted a total revenue of AUD 256.75 million, representing a 3.1% YoY increase …

Sonal Goyal | 21 August 2025

Atturra (ASX:ATA) Targets Over 20% Growth in FY26 Amid Acquisition-Driven Expansion

Atturra Limited (ASX:ATA), an ASX-listed advisory and technology solutions provider, has reported encouraging financial performance for the first half of the financial year 2025 (1HFY25) while advancing its expansion strategy through acquisitions and sector diversification.

Sonal Goyal | 19 August 2025

Suncorp Group (ASX:SUN) Posts 43% Profit Jump in FY25, Mid-Single Digit GWP Growth Expected in FY26

Suncorp Group Limited (ASX:SUN), a leading Trans-Tasman insurer with a history spanning more than a century, provides general insurance services and products to clients across New Zealand and Australia. In the year ended 30 June 2025 (FY25), Suncorp posted a Gross Written Premium (GWP) …

Sonal Goyal | 18 August 2025

Paradigm Biopharmaceuticals (ASX:PAR) Narrows Loss in H1 FY25, Advances Phase 3 Knee OA Trial

Paradigm Biopharmaceuticals Limited (ASX:PAR) is a clinical-stage biopharmaceutical company focused on developing pentosan polysulfate sodium (PPS) for the treatment of osteoarthritis and other inflammatory conditions. Its lead asset, Zilosul®, is in Phase 3 development, addressing significant unmet medical needs worldwide.

Sonal Goyal | 13 August 2025
Support

Hi! How can we help you today?

Loading…